Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion disclosed that while it signed an MOU with Yesan, South Chungcheong Province for a bio-pharmaceutical plant investment, detailed plans remain unconfirmed, with a re-disclosure planned once finalized or within 6 months.
📊 [Key Disclosure Details & Financial Highlights]
- Overview
- Title: Clarification on Rumors or Reports (Unconfirmed)
- Subject Report Content: Reports regarding “Celltrion to build South Chungcheong plant – 300B KRW investment by 2028”
- Media Outlet: Seoul Economic Daily and other news media
- Report Date: December 01, 2023
- Disclosure Type: Re-disclosure of the initial clarification disclosure dated December 01, 2023
- Clarification Details
- Celltrion signed a Memorandum of Understanding (MOU) with Yesan, South Chungcheong Province, for an investment of KRW 300 billion by December 2028 to build a plant for bio-pharmaceuticals and related materials.
- Specific investment plans are scheduled to be finalized in the future.
- Re-disclosure Schedule
- Expected Re-disclosure Date: September 27, 2024 (or when specific details are finalized)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Detailed Investment Plan Finalization and Re-disclosure
This disclosure is an unconfirmed clarification notice filed while detailed investment plans remain to be confirmed following the signing of an MOU with Yesan, South Chungcheong Province. Monitoring whether specific investment details are finalized in the future and tracking subsequent disclosures prior to the expected re-disclosure date (September 27, 2024) is important. Detailed updates can be verified in subsequent disclosures and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
